Powered by

-Flexion Therapeutics Announces FDA Clearance of the Investigational New Drug Application for FX201, a Gene Therapy Candidate for the Treatment of Osteoarthritis

Nov 01, 2019 - ENP Newswire

BURLINGTON - Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced clearance of the company's Investigational New Drug (IND) application for FX201 in knee osteoarthritis (OA), a painful, chronic and progressive disease that affects more than 15 million adults living in the United States.

Flexion has initiated a Phase 1 multicenter, open-label, single ascending dose study and expects to treat the first patient by the end of this year.

'Disease progression in osteoarthritis ...